World's Best Scientists 2026 revealed!
John R. Zalcberg

John R. Zalcberg

D-Index & Metrics

Medicine

D-Index
82
Citations
39469
World Ranking
15867
National Ranking
528

Research.com Recognitions

  • 2015 - Fellow of the Australian Academy of Health and Medical Science

Overview

John R. Zalcberg is affiliated with Monash University in Australia and conducts research primarily in the field of Medicine, with a focus on Oncology. Their work spans various subfields including Pulmonary and Respiratory Medicine, Surgery, Gastroenterology, and Economics and Econometrics.

The scientist's research topics prominently cover Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Gastrointestinal Tumor Research and Treatment, Pancreatic and Hepatic Oncology Research, Lung Cancer Treatments and Mutations, Genetic Factors in Colorectal Cancer, and Colorectal Cancer Screening and Detection.

Frequent publication venues for their research include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancers
  • Journal of Thoracic Oncology
  • European Journal of Cancer

Coauthors that John R. Zalcberg has frequently collaborated with include:

  • Aimery de Gramont
  • Benoist Chibaudel
  • Qian Shi
  • Rob G. Stirling
  • Richard Adams

Recent papers by John R. Zalcberg include:

  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial (2020, The Lancet Oncology)
  • Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network (2020, Annals of Oncology)
  • Effect of Aspirin on Cancer Incidence and Mortality in Older Adults (2020, JNCI Journal of the National Cancer Institute)
  • Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD (2020, Journal of Clinical Oncology)
  • Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial (2022, Journal of Clinical Oncology)

John R. Zalcberg was awarded the title of Fellow of the Australian Academy of Health and Medical Science in 2015.

Best Publications

  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

    Christos S Karapetis;Shirin Khambata-Ford;Derek J Jonker;Chris J O'Callaghan

  • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

    Charles S Fuchs;Jiri Tomasek;Cho Jae Yong;Filip Dumitru

  • Cetuximab for the Treatment of Colorectal Cancer

    Derek J Jonker;Chris J O'Callaghan;Christos S Karapetis;John R Zalcberg

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

    Katrin M Sjoquist;Bryan H Burmeister;B Mark Smithers;B Mark Smithers;John R Zalcberg

  • Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis

    Val Gebski;Bryan Burmeister;B Mark Smithers;Kerwyn Foo

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04

    Samuel Y K Ngan;Bryan H Burmeister;Richard John Fisher;Michael J Solomon

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

    Wendy De Roock;Derek J Jonker;Federica Di Nicolantonio;Andrea Sartore-Bianchi

  • Delivering affordable cancer care in high-income countries

    Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg

  • Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

    Niall C. Tebbutt;Kate Wilson;Val J. Gebski;Michelle M. Cummins

  • Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

    John R. Zalcberg;Jaap Verweij;Paolo G. Casali;Axel Le Cesne

  • A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

    James Dan Mellor;James Dan Mellor;Michael Brown;Helen Ruth Irving;John Raymond Zalcberg;John Raymond Zalcberg

  • Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

    S.Y. Brulé;D.J. Jonker;C.S. Karapetis;C.J. O’Callaghan

  • Randomized Trial of Coordinated Psychosocial Interventions Based on Patient Self-Assessments Versus Standard Care to Improve the Psychosocial Functioning of Patients With Cancer

    Sue-Anne McLachlan;Ann Allenby;Jane Matthews;Andrew Wirth

  • Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer

    Russell L. Basser;John E.J. Rasko;Kerrie Clarke;Jonathan Cebon

  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Jean Yves Blay;César Serrano;Michael C. Heinrich;John Zalcberg

  • Final results of a randomised trial comparing ‘Tomudex’ (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

    D Cunningham;J R Zalcberg;U Rath;I Oliver

Frequent Co-Authors

John Simes
John Simes University of Sydney
David Goldstein
David Goldstein University of New South Wales
Dongsheng Tu
Dongsheng Tu Queen's University
John J McNeil
John J McNeil Monash University
Val Gebski
Val Gebski University of Sydney
Malcolm J. Moore
Malcolm J. Moore Princess Margaret Cancer Centre
Danny Rischin
Danny Rischin Peter MacCallum Cancer Centre
Stephen J. Clarke
Stephen J. Clarke University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want to explore alternative or complementary healthcare paths, there are many flexible online degree options available. These pathways can help you enter healthcare fields sooner or specialize in high-demand roles.

For those interested in nursing, some nursing school no entrance exam programs eliminate barriers typically caused by admissions tests, making it easier for aspiring nurses to begin their studies right away.

If healthcare management piques your interest, pursuing a healthcare administration online degree can prepare you for leadership roles in hospitals, clinics, and other medical organizations. 

Registered nurses looking to advance their practice may consider rn to np bridge programs, which offer a streamlined path to becoming a nurse practitioner and expanding professional opportunities.

For a focus on preventive care and wellness, an online nutrition degree opens doors to careers in dietetics, public health, or fitness coaching.

Exploring these related online options can help you find the best fit for your interests and set you on a rewarding healthcare career path.

Best Scientists Citing John R. Zalcberg

Trending Scientists

Recently Published Articles